信达生物完成与武田制药战略合作相关协议

Group 1 - The core point of the article is that Innovent Biologics has completed a global strategic cooperation agreement with Takeda Pharmaceutical, involving the issuance of approximately 6.9138 million shares [1] - The shares issued represent 0.4% of the company's expanded total share capital, with a subscription price of HKD 112.56 per share, reflecting a premium of 20.3% over the previous trading day's closing price [1] - The total transaction amount is approximately HKD 778 million, with a net fundraising amount of about HKD 777 million after deducting related expenses [1]